UNCY
NASDAQUnicycive Therapeutics Inc.
Price$6.66-0.08 (-1.19%)
01:30 PM07:45 PM
News · 26 weeks290%
2025-12-142026-06-07
Mix2190d
- SEC Filings10(48%)
- Insider6(29%)
- Earnings2(10%)
- Other2(10%)
- Analyst1(5%)
Latest news
25 items- SECUnicycive Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Unicycive Therapeutics, Inc. (0001766140) (Filer)
- SECSEC Form S-3 filed by Unicycive Therapeutics Inc.S-3 - Unicycive Therapeutics, Inc. (0001766140) (Filer)
- INSIDERSEC Form 4 filed by Director Kenkare-Mitra Sara4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
- INSIDERSEC Form 4 filed by CEO Gupta Shalabh K.4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
- INSIDERSEC Form 4 filed by EVP, Corporate Strategy Jermasek Douglas4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
- INSIDERSEC Form 4 filed by CFO Townsend John4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
- INSIDERSEC Form 4 filed by EVP, Pharmaceuticals and BD Gupta Pramod4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
- INSIDERSEC Form 4 filed by Director Laumas Sandeep4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Unicycive Therapeutics Inc.SCHEDULE 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)
- SECUnicycive Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Unicycive Therapeutics, Inc. (0001766140) (Filer)
- PRUnicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business UpdateU.S. Food and Drug Administration (FDA) review of oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission remains on track, with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026Commercial readiness activities continue in anticipation of the potential commercial launch of OLC MOUNTAIN VIEW, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the first quarter ended March 31, 2026, and provided a business update. "As we approach the June 29th PDUFA target action date, we remain opti
- SECSEC Form 10-Q filed by Unicycive Therapeutics Inc.10-Q - Unicycive Therapeutics, Inc. (0001766140) (Filer)
- SECSEC Form S-8 filed by Unicycive Therapeutics Inc.S-8 - Unicycive Therapeutics, Inc. (0001766140) (Filer)
- ANALYSTB. Riley Securities initiated coverage on Unicycive Therapeutics with a new price targetB. Riley Securities initiated coverage of Unicycive Therapeutics with a rating of Buy and set a new price target of $22.00
- SECSEC Form DEFA14A filed by Unicycive Therapeutics Inc.DEFA14A - Unicycive Therapeutics, Inc. (0001766140) (Filer)
- SECSEC Form DEF 14A filed by Unicycive Therapeutics Inc.DEF 14A - Unicycive Therapeutics, Inc. (0001766140) (Filer)
- PRUnicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceLOS ALTOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 3:45 p.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead investi
- SECSEC Form 8-K filed by Unicycive Therapeutics Inc.8-K - Unicycive Therapeutics, Inc. (0001766140) (Filer)
- SECUnicycive Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Unicycive Therapeutics, Inc. (0001766140) (Filer)
- PRUnicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business UpdateOxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026Commercial readiness activities ongoing in anticipation of potential commercial launch of OLC in 3Q26As of March 30, 2026 unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, with expected runway into 2027 LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended D
- SECSEC Form 10-K filed by Unicycive Therapeutics Inc.10-K - Unicycive Therapeutics, Inc. (0001766140) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Unicycive Therapeutics Inc.SCHEDULE 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Unicycive Therapeutics Inc.SCHEDULE 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Unicycive Therapeutics Inc.SCHEDULE 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)
- PRUnicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech SummitLOS ALTOS, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026, at 1:30 p.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. To schedule a 1x1 meeting with management, please contact your Guggenheim conference representative. About Unicycive Therapeutics Uni
UNCY FAQ
7 questionsWhat does Unicycive Therapeutics Inc. do?
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.Where does UNCY stock trade?
Unicycive Therapeutics Inc. (UNCY) is listed on NASDAQ.What sector and industry is UNCY in?
Unicycive Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Unicycive Therapeutics Inc. go public?
Unicycive Therapeutics Inc. (UNCY) completed its IPO in 2021.What are analysts saying about UNCY?
Unicycive Therapeutics Inc. has had 4 recent analyst actions on file. The most recent action was from B. Riley Securities: Buy with a $2200.00 price target on 2026-05-01. Recent price targets range from $600.00 to $2200.00.What companies are similar to UNCY?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare UNCY side-by-side with any of them on Quantisnow.How can I track UNCY on Quantisnow?
Quantisnow aggregates Unicycive Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow UNCY to receive live email and push alerts on every new disclosure.